Qaasid News

Download Our App

Author: admin

Continue Reading

  • China says Japan sent 'shocking' wrong signal on Taiwan – Reuters

    1. China says Japan sent ‘shocking’ wrong signal on Taiwan  Reuters
    2. China spat with Japan on Taiwan deepens, reaches UN: What’s it all about?  Al Jazeera
    3. China says it will not allow Japanese ‘militarism to stage a comeback’  Anadolu Ajansı

    Continue Reading

  • Women’s Volleyball Season Ends with Loss to Long Beach State

    Women’s Volleyball Season Ends with Loss to Long Beach State

    HONOLULU — The University of Hawai’i women’s…

    Continue Reading

  • Mull’s 1940s romantic comedy that brought Gaelic to cinema

    Mull’s 1940s romantic comedy that brought Gaelic to cinema

    Ruairidh MaciverBBC Naidheachdan

    Getty Images A black and white image showing Roger Livesey, in a kilt, and Michael Powell, seated, as the cèilidh scene is recorded in I Know Where I'm Going.Getty Images

    Actor Roger Livesey, wearing a kilt, with director Michael Powell seated next to him during filming of a ceilidh

    Eighty years ago a small crowd gathered in a hall in Tobermory on Mull for a preview…

    Continue Reading

  • Independent Non-Executive Director of Bridgepoint Group Picks Up 100% More Stock

    Independent Non-Executive Director of Bridgepoint Group Picks Up 100% More Stock

    Investors who take an interest in Bridgepoint Group plc (LON:BPT) should definitely note that the Independent Non-Executive Director, Cyrus Russi Taraporevala, recently paid UK£2.84 per share to buy UK£284k worth of the stock. That certainly has us anticipating the best, especially since they thusly increased their own holding by 100%, potentially signalling some real optimism.

    AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

    Notably, that recent purchase by Cyrus Russi Taraporevala is the biggest insider purchase of Bridgepoint Group shares that we’ve seen in the last year. That means that an insider was happy to buy shares at above the current price of UK£2.72. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it’s very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Cyrus Russi Taraporevala.

    The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

    Check out our latest analysis for Bridgepoint Group

    LSE:BPT Insider Trading Volume November 23rd 2025

    Bridgepoint Group is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

    Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, Bridgepoint Group insiders have about 0.1% of the stock, worth approximately UK£2.3m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We prefer to see high levels of insider ownership.

    It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. While the overall levels of insider ownership are below what we’d like to see, the history of transactions imply that Bridgepoint Group insiders are reasonably well aligned, and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it’s also worthwhile knowing the risks facing this company. Our analysis shows 3 warning signs for Bridgepoint Group (1 is significant!) and we strongly recommend you look at these before investing.

    But note: Bridgepoint Group may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

    For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Continue Reading

  • Exploring Valuation as Shares Edge Up Despite Sector Uncertainty

    Exploring Valuation as Shares Edge Up Despite Sector Uncertainty

    Oceaneering International (OII) has caught some attention lately as its stock edged higher, gaining about 3% in the latest session. This uptick comes even as the broader energy sector presented mixed signals for investors.

    See our latest analysis for Oceaneering International.

    Oceaneering International’s recent share price gain builds on a gradually improving short-term trend, but momentum is still muted compared to last year’s performance. While the stock is up 3.29% in the last session, the one-year total shareholder return sits at -19.58%. This reminds investors of some lingering caution, even after impressive multi-year gains.

    If you’re keeping an eye on shifts in energy sector momentum, now is the perfect chance to broaden your search and discover fast growing stocks with high insider ownership

    With shares staging a modest rebound, the question now is whether Oceaneering International remains undervalued with more upside ahead, or if investors have already factored in future growth prospects at current levels.

    At $24.15 per share, Oceaneering International trades just above the consensus narrative fair value of $22.38, suggesting that the market anticipates robust operational progress and stable growth prospects.

    The company’s high dependency on cyclical offshore oil and gas spending, evident in bookings and utilization guidance, makes its revenues and earnings vulnerable to potential sharp downturns if energy prices fall or if capital expenditure plans of major clients decline, as indicated by flat book-to-bill ratios and conservative utilization outlooks.

    Read the complete narrative.

    What hidden numbers are driving analyst models this time? The narrative is based on detailed assumptions about future revenue streams, margin pressures, and strategic pivots that could change profits more rapidly than many anticipate. Want to know what financial forecasts are influencing this price target? Find out what could surprise investors by reading the full breakdown.

    Result: Fair Value of $22.38 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, continued growth in aerospace and defense contracts, or persistent strength in high-margin robotics, could boost earnings beyond current expectations.

    Find out about the key risks to this Oceaneering International narrative.

    While the market sees Oceaneering International as slightly overvalued based on analyst price targets, our DCF model presents a very different story. The SWS DCF model estimates fair value at $51.12, which is more than double the current share price. This suggests considerable undervaluation. Could analysts be overlooking hidden future cash flows?

    Look into how the SWS DCF model arrives at its fair value.

    OII Discounted Cash Flow as at Nov 2025

    If these perspectives do not fit your view, or you would rather dig into the numbers yourself, you can craft your own narrative in just a few minutes. Do it your way.

    A great starting point for your Oceaneering International research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    Give yourself a real edge by uncovering stocks in overlooked areas before the crowd catches on. Simply Wall Street’s screeners highlight unique opportunities many investors miss.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include OII.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Assessing Valuation Following Recent Share Price Volatility

    Assessing Valuation Following Recent Share Price Volatility

    Dave (DAVE) shares have experienced some notable ups and downs over the past month, catching the attention of investors watching the stock’s performance. Recent price shifts prompt a closer look at how the company is positioned in today’s market.

    See our latest analysis for Dave.

    Dave’s recent 6.7% jump in share price came after weeks of choppy trading, including a noticeable slide earlier in the month. Even with this volatility, momentum remains strong, as shown by its impressive year-to-date share price return of 125.56% and a truly staggering total shareholder return of 1,383.84% over the past three years.

    If you’re open to finding other remarkable growth stories in today’s market, now is the perfect moment to broaden your perspective and discover fast growing stocks with high insider ownership

    But with Dave’s current share price still trading well below analysts’ targets, the key question remains: does this signal an undervalued opportunity, or has the market already factored in the company’s growth prospects?

    With Dave’s last closing price standing well below its most popular narrative’s fair value, debate is swirling on what’s truly fueling this perceived upside. As analysts weigh enthusiasm against new profitability forecasts, one insight stands out as a defining catalyst.

    Enhanced monetization from fee structure changes, including a successful rollout of a $3 monthly subscription fee (with no measurable negative impact on retention), offers meaningful ARPU and LTV uplift, further supported by secular demand for transparent, low-fee banking alternatives. This directly supports revenue growth and margin expansion.

    Read the complete narrative.

    Want to know what’s behind this big valuation gap? The narrative pivots on bold fee strategies, new margin targets, and revenue projections that defy industry norms. Ready to see the financial leap that drives this astounding fair value?

    Result: Fair Value of $285 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, there are still questions about tightening regulations on fee-based models. There is also the possibility that shifting consumer preferences could dampen demand.

    Find out about the key risks to this Dave narrative.

    If you see things differently or want to conduct your own research, it only takes a few minutes to build your own perspective. Do it your way

    A great starting point for your Dave research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

    Smart moves today start with seeking out the freshest ideas. Don’t miss your chance to find stocks reinventing tomorrow. These screens highlight what others overlook.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include DAVE.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Can overdose of vitamin C cause kidney failure? Nausea, diarrhoea and kidney stone risks explained |

    Can overdose of vitamin C cause kidney failure? Nausea, diarrhoea and kidney stone risks explained |

    If you have ever taken large doses of vitamin C to boost immunity or recover from a cold, you are not alone. Many people assume vitamin C is completely harmless because it is water-soluble and the body flushes out whatever it does not need. But…

    Continue Reading

  • GLP-1 Agonists Linked to Hidradenitis Suppurativa Care

    GLP-1 Agonists Linked to Hidradenitis Suppurativa Care

    A NOVEL study has shown that Glucagon-like peptide-1 (GLP-1) agonists, medications widely used for obesity and type 2 diabetes, may offer benefits for patients with hidradenitis suppurativa (HS), a chronic inflammatory skin condition often…

    Continue Reading